期刊文献+

脂肪肉瘤临床与分子特征及药物治疗进展 被引量:3

Clinical and molecular characteristics of liposarcoma and drug treatment progress
下载PDF
导出
摘要 脂肪肉瘤是源于脂肪细胞的一组异质性软组织肉瘤,根据组织学特征可分为高分化脂肪肉瘤、去分化脂肪肉瘤、黏液/圆细胞及多形性脂肪肉瘤等亚型。不同亚型具有特异的驱动基因和分子机制,故相应靶向药物或特异性治疗药物亦不相同。新型细胞毒药物艾立布林,靶向药物CDK4/6抑制剂、MDM2抑制剂,免疫检查点抑制剂PD-1/PD-L1单抗等治疗去分化脂肪肉瘤获益显著,而曲贝替定、XPO1抑制剂和NY-ESO-1对黏液/圆细胞脂肪肉瘤疗效较佳。明确脂肪肉瘤亚型,根据不同亚型制定个体化治疗策略可进一步改善脂肪肉瘤患者的生存质量。 Liposarcoma is a group of heterogeneous soft tissue sarcomas derived from adipocytes.According to histological characteristics,liposarcoma can be divided into four subtypes:Well-differentiated liposarcoma,dedifferentiated liposarcoma,myxoid/circular cell and pleomorphic liposarcoma.Different subtypes have specific driving genes and molecular mechanisms,so the corresponding targeted drugs or specific therapeutic drugs are also different.The treatment of dedifferentiated liposarcoma with new cytotoxic drugs such as eribulin,targeted drugs such as CDK4/6 inhibitor,MDM2 inhibitor,and immune checkpoint inhibitor PD-1/PD-L1 monoclonal antibody were significantly beneficial,while trabectedin,XPO1 inhibitor and NY-ESO-1 were more effective in the treatment of myxoid/circular cell liposarcoma.Identifying the subtypes of liposarcoma and formulating individualized treatment strategies according to different subtypes can further improve the survival of patients with liposarcoma.
作者 任静祎 王祥旭 孔胜男 刘文超 张红梅 REN Jingyi;WANG Xiangxu;KONG Shengnan;LIU Wenchao;ZHANG Hongmei(Department of Oncology,Xijing Hospital,Air Force Medical University,Shaanxi Xi'an 710032,China)
出处 《现代肿瘤医学》 CAS 2020年第24期4359-4362,共4页 Journal of Modern Oncology
基金 国家自然科学基金面上项目(编号:81572699) 陕西省重点产业创新链课题(编号:2016KTZDSF-01-05)。
关键词 脂肪肉瘤 临床特征 分子特征 药物治疗 liposarcoma clinical features molecular pathology pharmacotherapy
  • 引文网络
  • 相关文献

同被引文献30

引证文献3

二级引证文献9

;
使用帮助 返回顶部